Clinical trials: Stage IV
Leukemia, Lymphoma
Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematological Cancer or Other Disease
RATIONALE: Giving low doses of chemotherapy and total-body irradiation before a donor umbilical cord blood transplant helps stop the growth of cancer or abnormal cells.
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT00719849
- Testing
- anti-thymocyte globulin, cyclophosphamide, cyclosporine
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Fred Hutchinson Cancer Center
Ciliary Body and Choroid Melanoma, Medium/Large Size, Ciliary Body and Choroid Melanoma, Small Size
Cixutumumab in Treating Patients With Metastatic Melanoma of the Eye
This phase II trial studies how well giving cixutumumab works in treating patients with metastatic melanoma of the eye. Monoclonal antibodies, such as cixutumumab, can block tumor growth in different ways.
- Conditions
- Ciliary Body and Choroid Melanoma, Medium/Large Size, Ciliary Body and Choroid Melanoma, Small Size, Iris Melanoma, Metastatic Intraocular Melanoma
- Trial name
- NCT01413191
- Testing
- Cixutumumab, Laboratory biomarker analysis
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- National Cancer Institute (NCI)
Adult Hepatocellular Carcinoma, Advanced Adult Hepatocellular Carcinoma
Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer
This phase II trial studies how well temsirolimus and bevacizumab work in treating patients with advanced endometrial, ovarian, liver, carcinoid, or islet cell cancer.
- Conditions
- Adult Hepatocellular Carcinoma, Advanced Adult Hepatocellular Carcinoma, Endometrial Serous Adenocarcinoma, Localized Non-Resectable Adult Liver Carcinoma
- Trial name
- NCT01010126
- Testing
- Bevacizumab, Temsirolimus
- Where
- 61 sites in United States, Canada
- Volunteers
- 252 people
- Sponsor
- National Cancer Institute (NCI)
Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III Squamous Cell Carcinoma of the Larynx
Cetuximab and Radiation Therapy in Treating Patients With Stage III-IV Head and Neck Cancer
This pilot clinical trial studies cetuximab and radiation therapy in treating patients with stage III-IV head and neck cancer. Monoclonal antibodies, such as cetuximab, may block tumor growth in different ways by targeting…
- Conditions
- Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III Squamous Cell Carcinoma of the Larynx, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage III Verrucous Carcinoma of the Larynx
- Trial name
- NCT02177838
- Testing
- cetuximab, cisplatin, external beam radiation therapy
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Rutgers, The State University of New Jersey
Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia
Fludarabine Phosphate, Radiation Therapy, and Rituximab in Treating Patients Who Are Undergoing Donor Stem Cell Transplant Followed by Rituximab for High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
This phase II trial studies how well fludarabine phosphate with radiation therapy and rituximab followed by donor stem cell infusions work in treating patients with high-risk chronic lymphocytic leukemia (CLL) or small…
- Conditions
- Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia
- Trial name
- NCT00104858
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Cyclosporine, Fludarabine Phosphate
- Where
- 5 sites in United States, Denmark and 1 more
- Volunteers
- 66 people
- Sponsor
- Fred Hutchinson Cancer Center
BRAF V600E Mutation Present, BRAF V600K Mutation Present
Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
This phase I trial studies the side effects and best dose of onalespib when given together with dabrafenib and trametinib in treating patients with BRAF-mutant melanoma or solid tumors that have spread to another place in the…
- Conditions
- BRAF V600E Mutation Present, BRAF V600K Mutation Present, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma
- Trial name
- NCT02097225
- Testing
- Dabrafenib, Laboratory Biomarker Analysis, Onalespib
- Where
- 2 sites in United States
- Volunteers
- 22 people
- Sponsor
- National Cancer Institute (NCI)
Fabry Disease
Safety, Efficacy, & PK of PRX-102 in Patients With Fabry Disease Administered Intravenously Every 4 Weeks
This open-label switchover study will assess the safety, efficacy, and pharmacokinetics of pegunigalsidase alfa (PRX-102) 2 mg/kg administered every 4 weeks for 52 weeks in Fabry patients previously treated with ERT: agalsidase…
- Trial name
- BRIGHT (NCT03180840)
- Testing
- Pegunigalsidase alfa
- Where
- 14 sites in United States, Belgium and 5 more
- Volunteers
- 30 people
- Sponsor
- Protalix
Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Non-Small Cell Cancer AJCC v7
Azacitidine in Treating Patients With Previously Treated Advanced Non-Small Cell Lung Cancer
This phase II clinical trial is studying how well azacitidine works in treating patients with previously treated advanced non-small cell lung cancer.
- Trial name
- NCT01281124
- Testing
- Azacitidine, Diagnostic Laboratory Biomarker Analysis, Pharmacological Study
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- National Cancer Institute (NCI)
Liver Cirrhosis
A Study to Compare How Different Substances (Caffeine, Warfarin, Omeprazole, Metoprolol, and Midazolam) Are Handled by the Body of Healthy People and People With Liver Cirrhosis
This study is open to healthy adults and adults with liver cirrhosis. The purpose of this study is to compare how different medicines are handled by the body in people with and without liver cirrhosis.
- Trial name
- NCT05741385
- Testing
- Caffeine, Warfarin sodium, Omeprazole
- Where
- Germany
- Volunteers
- 4 people
- Sponsor
- Boehringer Ingelheim
Lung Cancer
Pemetrexed Disodium and Gemcitabine in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
RATIONALE: Pemetrexed disodium may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop the growth of tumor cells…
- Trial name
- NCT00407550
- Testing
- gemcitabine HCL, pemetrexed disodium
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Mayo Clinic
Advanced Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8
68Ga PSMA PET Imaging for the Treatment of Advanced Liver Cancer
This phase II trial tests whether 68-Gallium prostate specific membrane antigen (68Ga-PSMA) positron emission tomography (PET) imaging can improve the diagnosis and management of liver cancer that has spread to other parts of the…
- Conditions
- Advanced Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Unresectable Hepatocellular Carcinoma
- Trial name
- NCT05176223
- Testing
- Computed Tomography, Gallium Ga 68 Gozetotide, Positron Emission Tomography
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Mayo Clinic
Relapsing-remitting Multiple Sclerosis
Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis
The primary objective of the study is to assess the clinical efficacy of Rebif® 44 microgram (mcg) three times per week compared with Copaxone® 20 milligram (mg) daily in subjects with relapsing Multiple Sclerosis.
- Trial name
- NCT00078338
- Testing
- Rebif®, Copaxone®
- Where
- 80 sites in United States, Argentina and 10 more
- Volunteers
- 764 people
- Sponsor
- EMD Serono
Infections, Meningococcal
Evaluation of Antibody Persistence Following 4 MenACWY Vaccinations
This is Phase IV, Open label, Multicenter study. Subject's parents and/or legal guardian will be provided information about the trial. If interested and if eligible, they will then be asked to provide signed informed consent.
- Trial name
- NCT02446691
- Testing
- MenACWY
- Where
- 6 sites in South Korea
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Mucosal Melanoma, Recurrent Melanoma
Temsirolimus/AZD 6244 for Treatment-naive With BRAF Mutant Unresectable Stage IV
The purpose of this study is to find out how often two investigational drugs that are given together will shrink the patient's tumor and how well they will prolong the time it takes their tumor to grow.
- Conditions
- Mucosal Melanoma, Recurrent Melanoma, Stage IV Melanoma
- Trial name
- NCT01166126
- Testing
- temsirolimus, selumetinib, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- National Cancer Institute (NCI)
Hereditary Thyroid Gland Medullary Carcinoma, Locally Advanced Thyroid Gland Medullary Carcinoma
Sorafenib Tosylate in Treating Patients With Metastatic, Locally Advanced, or Recurrent Medullary Thyroid Cancer
This phase II trial studies how well sorafenib tosylate works in treating patients with medullary thyroid cancer that has spread to other parts of the body (metastatic), spread to the tissue surrounding the thyroid (locally…
- Conditions
- Hereditary Thyroid Gland Medullary Carcinoma, Locally Advanced Thyroid Gland Medullary Carcinoma, Multiple Endocrine Neoplasia Type 2A, Multiple Endocrine Neoplasia Type 2B
- Trial name
- NCT00390325
- Testing
- Sorafenib Tosylate
- Where
- 3 sites in United States
- Volunteers
- 21 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Pancreatic Ductal Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8
Niraparib and Dostarlimab for the Treatment of Germline or Somatic BRCA1/2 and PALB2 Mutated Metastatic Pancreatic Cancer
This phase II trial studies how well niraparib and dostarlimab work in treating patients with germline or somatic BRCA1/2 and PALB2 mutated pancreatic cancer that has spread to other places in the body (metastatic).
- Trial name
- NCT04493060
- Testing
- Dostarlimab, Niraparib
- Where
- 3 sites in United States
- Volunteers
- 22 people
- Sponsor
- Mayo Clinic
Carcinoma, Non-Small-Cell Lung
M7824 in Combination With Chemotherapy in Stage IV Non-small Cell Lung Cancer (NSCLC)
The main purpose of the study was to evaluate the safety and tolerability of M7824 in combination with chemotherapy.
- Trial name
- NCT03840915
- Testing
- Cisplatin, Carboplatin, Pemetrexed
- Where
- 19 sites in United States, Belgium and 1 more
- Volunteers
- 70 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Non-Small Cell Lung Cancer
An Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) Monotherapy in Subjects With Advanced or Metastatic Squamous Cell (Sq) Non-Small Cell Lung Cancer (NSCLC) Who Have Received at Least One Prior Systemic Regimen for the Treatment of Stage IIIb/IV SqNSCLC
The purpose of the study is to determine the occurrence of high-grade (CTCAE v4.0 Grades 3-4), treatment-related, select adverse events in patients with advanced or metastatic Squamous Cell Non-Small Cell Lung Cancer (SqNSCLC)…
- Trial name
- Checkmate 171 (NCT02409368)
- Testing
- Nivolumab
- Where
- 90 sites in Austria, Denmark and 11 more
- Volunteers
- 812 people
- Sponsor
- Bristol-Myers Squibb
Melanoma (Skin)
Vaccine Therapy in Treating Patients With Metastatic Melanoma
RATIONALE: Vaccines made from peptide 946 may make the body build an immune response to kill tumor cells. Combining these vaccines with proteins from the tetanus vaccine, and/or with either QS21 or Montanide ISA-51 may be an…
- Trial name
- NCT00003224
- Testing
- QS21, IFA (incomplete Freund's adjuvant), p946
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- University of Virginia
Breast Cancer
S0430 Cyclophosphamide and Capecitabine in Treating Women With Stage IV Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00107276
- Testing
- capecitabine, cyclophosphamide
- Where
- 145 sites in United States
- Volunteers
- 112 people
- Sponsor
- SWOG Cancer Research Network
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.